THURSDAY, July 24, 2025 (HealthDay News) -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause ...

Study Rundown: Studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of various forms of dementia, including vascular dementia and Alzheimer’s disease.

HealthDay News — For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1 RAs ...

Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report 2025-2034 Featuring Eli Lilly and Co, Sanofi,, Novo Nordisk, and AstraZeneca - ResearchAndMarkets.com ...

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Report 2025-2034 | Substantial Investments to Support R&D and Boost Production - ResearchAndMarkets.com ...

The number of Americans on incretin-based therapies, such as glucagon-like peptide 1 receptor agonists (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA has increased by ...

Ecnoglutide, a novel glucagon -like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data ...

Glucagon-like peptide-1 (GLP-1) is one of the hormones that the body produces to initiate satiety, the feeling of being full. GLP-1 hormone is a natural appetite suppressant.

Glucagon-like-peptide-1 agonists like Ozempic have become extremely popular for weight loss. Here are some of the side effects you should know about.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.